瑞舒伐他汀钙联合美托洛尔对心力衰竭患者心功能的影响及其安全性

发布时间：2018-05-30 21:53

本文选题：瑞舒伐他汀钙 + 美托洛尔　；参考：《中国老年学杂志》2017年15期

【摘要】：目的探讨瑞舒伐他汀钙联合美托洛尔对心力衰竭患者心功能的影响及其安全性。方法回顾性分析该院治疗心力衰竭患者84例临床案例,按照给药方式不同分为联合用药组和单一用药组各42例。单一用药组给予常规抗心力衰竭治疗和使用瑞舒伐他汀钙5 mg/次,1次/d;联合用药组在此基础上加用美托洛尔25 mg/次,2次/d,疗程均为3个月。统计分析两组治疗后疗效情况、治疗前后心功能指标情况及治疗期间出现不良反应情况。结果经过3个月治疗后,两组均得到显著治疗效果,而联合用药组总有效率高于单一用药组(P0.05);经过治疗1、3个月后,两组心功能指标均得到一定程度改善,其中治疗1个月及治疗3个月后联合用药组左心室舒张末期内径(LVDD)、左室收缩末期内径(LVESD)均低于单一用药组,而左室射血分数(LVEF)高于单一用药组(P0.05);治疗期间,两组均出现轻微不良反应,经对症处理后,症状均改善,两组总不良反应发生率差异无统计学意义(P0.05)。结论瑞舒伐他汀钙联合美托洛尔治疗心力衰竭患者不仅能提高治疗效果,还能进一步改善患者心功能,而且安全性高。
[Abstract]:Objective to investigate the effect and safety of recuvastatin calcium combined with metoprolol on cardiac function in patients with heart failure. Methods 84 patients with heart failure were analyzed retrospectively. According to the different ways of administration, the patients were divided into two groups: the combined group and the single group. The patients in the single drug group were treated with conventional anti-heart failure therapy and with recuvastatin calcium for 5 mg/ d, and the combination group were treated with metoprolol for 25 mg/ d for 3 months. The curative effect, cardiac function index and adverse reaction during treatment were analyzed statistically. Results after 3 months of treatment, the two groups had significant therapeutic effects, and the total effective rate of the combined treatment group was higher than that of the single drug group (P 0.05), and after 1 and 3 months of treatment, the cardiac function indexes of both groups were improved to a certain extent. The left ventricular end-diastolic diameter (LVDDD), left ventricular end-systolic diameter (LVESD) and left ventricular ejection fraction (LVEF) in the combined treatment group were lower than those in the monotherapy group, and the left ventricular ejection fraction (LVEF) was higher than that in the monotherapy group (P 0.05). There were slight adverse reactions in both groups, and the symptoms were improved after symptomatic treatment. There was no significant difference in the incidence of total adverse reactions between the two groups (P 0.05). Conclusion Risuvastatin calcium combined with metoprolol in the treatment of heart failure patients can not only improve the therapeutic effect, but also further improve the heart function of patients, and high safety.
【作者单位】：内蒙古医科大学附属医院;
【分类号】：R541.6

【相似文献】